Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
PROMIMIC Aktie jetzt für 0€ handeln | |||||
18.02. | Karolinska Development AB (publ): Karolinska Developments portfolio company Promimic publishes positive results on reduction of bacteria growth on HAnano Surface | 123 | GlobeNewswire (Europe) | STOCKHOLM, SWEDEN, February 18 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Promimic has published positive results showing a reduction of bacterial... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
MEDTRONIC | 74,91 | +1,19 % | Medtronic Submits 510(k) Application To FDA For Interoperable Insulin Pump | WASHINGTON (dpa-AFX) - Medtronic plc (MDT), Thursday announced it has submitted 510(k) applications to the U.S. Food and Drug Administration (FDA) seeking clearance for an interoperable pump.... ► Artikel lesen | |
HCA HEALTHCARE | 298,60 | -0,43 % | AbbVie, Colgate-Palmolive, HCA Holdings lead Friday's earnings parade | ||
LANTHEUS | 92,42 | +1,58 % | Lantheus Holdings, Inc.: Lantheus Completes Acquisition of Evergreen Theragnostics | BEDFORD, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians... ► Artikel lesen | |
AMEDISYS | 82,00 | 0,00 % | Amedisys Q1 Profit Increases, Beats Estimates | WASHINGTON (dpa-AFX) - Amedisys (AMED) announced earnings for its first quarter that increased from the same period last year and beat the Street estimates.The company's bottom line totaled... ► Artikel lesen | |
ENVISTA | 14,100 | 0,00 % | Bausch + Lomb To Return EnVista Intraocular Lenses To Market Following Recall; Stock Up | ||
CAREDX | 16,850 | +3,72 % | CareDx, Inc.: CareDx gibt Studie bekannt, die zeigt, dass AlloSeq cfDNA bei der Erkennung von Abstoßungsreaktionen bei Organtransplantationspatienten äußerst genau ist | AlloSeq cfDNA entspricht der Leistung des bewährten AlloSure-Tests CareDx bringt mit AlloSeq cfDNA ein innovatives nicht-invasives Transplantationsmonitoring für Patienten auf internationaler... ► Artikel lesen | |
SYNEOS HEALTH | - | - | Research Solutions, Inc.: Research Solutions Reports Fiscal Second Quarter 2025 Results | Reports 23 Percent Increase in ARR to $19.1 Million and 61 Net New Platform Deployments HENDERSON, Nev., Feb. 13, 2025 /PRNewswire/ -- Research Solutions, Inc. (NASDAQ: RSSS), the leading... ► Artikel lesen | |
GT BIOPHARMA | 2,330 | 0,00 % | GT Biopharma, Inc. - 10-K/A, Annual Report | ||
CARMAT | 0,885 | +0,91 % | CARMAT Receives FDA Conditional Approval to Initiate the Second Cohort of the EFS Study in the United States | Recruitment of the second cohort expected to begin in H2 2025
Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming... ► Artikel lesen | |
CHEMOMETEC | 63,35 | -0,47 % | Chemometec A/S: Interim report 2024/25 - Solid H1 performance driven by growth in both revenue and earnings | ANNOUNCEMENT NO. 2875 February 2025 Solid H1 performance driven by growth in both revenue and earnings Martin Helbo Behrens, CEO: The growth continued in the second quarter of 2024/25, and revenue... ► Artikel lesen | |
HAMILTON THORNE | 1,490 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.12.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 02.12.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.12.2024ISIN NameCA81012R1064 SCOTTIE... ► Artikel lesen | |
POLAREAN IMAGING | 0,001 | -93,33 % | Polarean Imaging PLC - Notice of Results | ||
ARRAIL GROUP | 0,180 | 0,00 % | ARRAIL GROUP (06639): NEXT DAY DISCLOSURE RETURNS | ||
DEVYSER DIAGNOSTICS | 9,050 | 0,00 % | Devyser Diagnostics AB: Jan Wahlström new CEO for Devyser | Devyser's board has appointed Jan Wahlström as new CEO, effective August 4.Jan Wahlström has a long background in leading and developing companies in the Health Care and Life Science areas internationally.... ► Artikel lesen | |
FRESENIUS | 39,850 | +0,94 % | ANALYSE-FLASH: Barclays senkt Ziel für Fresenius SE - 'Overweight' | LONDON (dpa-AFX Broker) - Die britische Investmentbank Barclays hat das Kursziel für Fresenius von 44,00 auf 43,50 Euro gesenkt, aber die Einstufung auf "Overweight" belassen. Die Bad Homburger dürften... ► Artikel lesen |